SADDLE BROOK, N.J., Oct. 28, 2010 (GLOBE NEWSWIRE) -- Herborium Group, Inc., (Pink Sheets:HBRM) , a Botanical Therapeutics™ company, today announced its 2011 marketing strategy, developed to increase market share of the world's natural medicines market.
"Having been in development for some time now, our 'path-to-market' explains Herborium's core strategy to capture market share – distinguishing our medicinal products with U.S. Food & Drug Administration (FDA) allowed labeling," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer. "I believe our three-tier path-to-market, soon available at , sets forth a sustainable, well thought out approach to development of our product pipeline."
Recent FDA guidelines (FDA Guidance for Industry: Botanical Drug Products), provide a mechanism to perform the clinical research necessary to enable Herborium to advertise medical claims for its proprietary botanical products including AcnEase® its flagship product, ().
"Furthermore, when one considers that Accutane®, a prescription only systemically acting acne medication marketed by Roche Pharmaceutical, is currently embroiled in class action lawsuits due to its alleged deleterious side effects, the opportunity for AcnEase becomes clear; aggressively establish AcnEase as the only oral, systemically acting acne medication with clinical trial validation of its safety & efficacy and fill Accutane's void."
An estimated 120 million women and men, including more than 30 million adults, suffer from some form of acne in the U.S. and top five European markets. The global pharmaceutical acne market, which was $2.5 billion in 2006, is forecast to grow to over $3 billion by 2016.
"With Herborium's healthy pipeline of additional Botanical Therapeutics currently in development, we expect to apply this overall market strategy to new products as well.
"In conclusion, since the development and marketing of medicines itself tends to be a complicated process, I look forward to soon visiting with our shareholders to answer questions and further explain how we intend to capture market share with this promising new classification of medicines," Olszewski concluded.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanically based medicinal products to consumers and healthcare professionals. The Company's business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit and .
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.
CONTACT: Herborium Group, Inc. Dr. Agnes P. Olszewski, President & CEO (201) 647-3757